Renal Transplant Rejection Clinical Trial
— HOT2Official title:
Heme Arginate in Transplantation Study - a Multi-centre Blinded Parallel-group Randomised Trial of Heme Arginate Versus Placebo to Reduce Delayed Graft Function in Kidney Transplant Recipients
Verified date | June 2021 |
Source | University of Edinburgh |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Organ shortage for transplant has necessitated use of kidneys from older donors, increasing the chance that the kidney will not work immediately or for as long as expected. The investigators gave the drug heme arginate (HA) to 20 kidney transplant patients in the first 24 hours after transplant, and showed that it may reduce kidney injury and is safe. The investigators plan to conduct a large study recruiting 600 patients to determine whether HA treatment increases the number of kidney transplants that work immediately. If successful, HA may be introduced into clinical practice at the end of this study. Patients will be invited to take part in the study once listed for a kidney transplant. Further discussions will be had with them when admitted for transplant, and they will be offered the opportunity to participate. Consent will not be taken until the patient is admitted for transplantation. Following consent, participants will be randomised to receive either 2 doses of the study drug, HA, or a salt water solution, one at the time of transplant, and one approximately 24 hours later. Otherwise, treatment will be the same as any other patient undergoing a kidney transplant. Information about recovery from surgery, and specifically about kidney function, will be collected, but will not require additional blood tests. The study period ends after the first 7 days post-transplant, although longer term data will be collected from routine follow up appointments. Participants will be asked to complete a simple quality of life questionnaire 3 times: just before transplant, at approximately one week and three months after transplant.
Status | Terminated |
Enrollment | 47 |
Est. completion date | February 23, 2021 |
Est. primary completion date | March 17, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients undergoing a kidney only transplant, or a dual kidney transplant, from a deceased donor - At least 18 years of age, no upper limit - Receiving standard immunosuppression for the individual centre - (where applicable) Meets co-enrolment criteria outlined in section 4.4 of the protocol Exclusion Criteria: - Kidney transplant patients as part of a multi-organ transplant e.g. with pancreas or liver - Known hypersensitivity to heme arginate - Unable to give informed consent - Patients with porphyria, irrespective of whether they have received heme arginate or not, will be excluded - Previous randomisation into this study (or HOT study) - Women who are pregnant or lactating - Kidneys that have undergone Ex-vivo Normothermic Perfusion (EVNP) - Patients with known liver disease, epilepsy, brain injury or disease |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh | Edinburgh | |
United Kingdom | NHS Lothian - Royal Infirmary of Edinburgh | Edinburgh | Lothian |
Lead Sponsor | Collaborator |
---|---|
University of Edinburgh | Kidney Cancer UK |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | 1 Year graft survival | Graft survival rates at 1 year post transplant will be obtained from routinely collected data and differences between treatment groups assessed. | 1 year | |
Other | 1 year recipient survival | Recipient survival rates at 1 year post transplant will be obtained from routinely collected data and differences between treatment groups assessed. | 1 year | |
Primary | Delayed Graft Function | The incidence of delayed graft function, defined as failure of a spontaneous fall in creatinine of >10% for each 3 consecutive day period in the first week following transplantation, with comparison between the two randomised groups. | 1 week post transplant | |
Secondary | Requirement for dialysis | The number of participants requiring dialysis within the first week post-transplant | 1 week post transplant | |
Secondary | Time to functioning graft | The number of days to functioning graft, defined as the spontaneous fall in creatinine of greater than, or equal to 10% over a period of 3 consecutive days in the first 7 days post transplant | 1 week | |
Secondary | Length of hospital stay | The number of days spent in hospital, along with level of care (ward/HDU/ITU), for the index admission (transplantation admission) | 3 months | |
Secondary | Creatinine levels | Serum creatinine levels at 1 and 3 months post-transplant across both randomised groups | 3 months | |
Secondary | Acute rejection | The number of participants with biopsy-proven acute rejection within the first 3 months post-transplant | 3 months | |
Secondary | SF36 Quality of Life | A comparison of differences between groups in patient reported quality of life using the SF36 | Up to 3 months post transplant | |
Secondary | Cost per QALY gained | Using data derived from the SF36 to weight survival for quality of life, Quality Adjusted Life Year (QALY) will be assessed | Up to 3 months post transplant |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03140514 -
Urine CXCL10 Chemokine Monitoring Post-renal Transplant
|
N/A | |
Completed |
NCT02581436 -
Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR
|
N/A | |
Active, not recruiting |
NCT02409940 -
To Elucidate the Effect of Mesenchymal Stem Cells on the T Cell Repertoire of the Kidney Transplant Patients
|
Phase 1 | |
Completed |
NCT02377193 -
Simulect Versus ATG in Sensitized Renal Transplant Patient
|
Phase 4 | |
Completed |
NCT00771745 -
Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients
|
Phase 4 | |
Not yet recruiting |
NCT05385432 -
Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies
|
Phase 3 | |
Completed |
NCT01953120 -
Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)
|
Phase 4 | |
Terminated |
NCT01324934 -
Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids
|
Phase 3 | |
Terminated |
NCT00983645 -
A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity
|
Phase 4 | |
Active, not recruiting |
NCT04530630 -
Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant
|
Phase 4 | |
Recruiting |
NCT03707262 -
Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor
|
Phase 1/Phase 2 | |
Completed |
NCT02006108 -
Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance
|
N/A | |
Recruiting |
NCT03991780 -
Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection
|
Phase 1/Phase 2 | |
Completed |
NCT02733029 -
Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection
|
Phase 2 | |
Active, not recruiting |
NCT02057965 -
Mesenchymal Stromal Cell Therapy in Renal Recipients
|
Phase 2 | |
Completed |
NCT00658073 -
Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts
|
N/A | |
Completed |
NCT02866682 -
Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients
|
Phase 4 | |
Not yet recruiting |
NCT06438107 -
Deep Phenotyping of the Renal Allograft to Prognosticate Clinical Outcomes
|
||
Completed |
NCT02500251 -
Belimumab Impacting Transplant Eligibility
|
Phase 1/Phase 2 | |
Completed |
NCT00866879 -
Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients
|
Phase 4 |